Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3110-3113

  Anderluh, Petra Štefanič ^a   Anderluh, Marko ^a   Ilaš, Janez ^a   Mravljak, Janez ^a   Dolenc, Marija Sollner ^a   Stegnar, Mojca ^b   Kikelj, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZOXAZIN 3(4H) ONE DERIVATIVE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ARGINYLGLYCYLASPARTIC ACID; BENZOXAZINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; COLLAGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THROMBIN INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTICLE; COMPLEX FORMATION; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVE SITE; IC 50; MOLECULAR INTERACTION; PERCUTANEOUS CORONARY INTERVENTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; BENZOXAZINES; FACTOR XA; FIBRINOGEN; FIBRINOLYTIC AGENTS; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR WEIGHT; OLIGOPEPTIDES; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, FIBRINOGEN; THROMBIN;

EID: 18244394034     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048984g     Document Type: Article

References (33)

1. Murray, C. J. L.; Lopez, A. D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997, 349, 1269-1276.
2. Ruef, J.; Katus, H. A. New antithrombotic drugs on the horizon. Expert Opin. Invest. Drugs 2003, 12, 781-797.
3. Steinmetzer, T.; Stürzebecher, J. Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr. Med. Chem. 2004, 11, 2297-2321.
4. Gould, W. R. Recent advances in the discovery and development of direct coagulation Factor Xa inhibitors. Curr. Pharm. Des. 2003, 9, 2337-2347.
5. Andronati, S. A.; Karaseva, T. L.; Krysko, A. A. Peptidomimetics- Antagonists of the fibrinogen receptor: Molecular design, structures, properties and therapeutic applications. Curr. Med. Chem. 2004, 11, 1183-1211.
6. Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethyl ketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467-3475.
7. Crowther M. A.; Weitz, J. I. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin. Invest. Drugs 2004, 13, 403-413.
8. Zablocki, A. J.; Rico, J. G.; Garland, R. B. et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidmo)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J. Med. Chem. 1995, 38, 2378-2394.
9. Bonow, R. O.; Carabello, B.; de Leon, A. C. et al. ACC/AHA Guidelines for the management of patients with valvular heart disease. J. Heart Valve Dis. 1998, 7, 672-707.
10. Nicolini, F. A.; Lee, P.; Rios, G.; Kottke-Marchant, K.; Topol, E. J. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low dosis markedly improves thrombolysis. Circulation 1994, 89, 1802-1809.
11. Sabatine, M. S.; Tu, T. M.; Jang, I.-K. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintaines reperfusion of platelet-rich thrombus with alteplase. J. Thromb. Thrombolysis 2000, 10, 189-196.
12. Wallenga, J. M.; Jeske, W. P.; Wallis, D. E.; Bakhos, M.; Lewis, B. E.; Leya, F.; Fareed, J. Clinical experience with combined treatment of thrombin inhibitors and GP IIb/IIIa inhibitors in patients with HIT. Semin. Thromb. Hemostasis 1999, 25, Suppl. 1, 77-81.
13. Lincoff, A. M.; Bittl, J. A.; Harrington, R. A. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention- REPLACE-2 randomized trial. JAMA 2003, 289, 853-863.
14. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
15. Church, F. C.; Phillips, J. E.; Woods, J. L. Chimeric antithrombin peptide-Characterization of an Arg-Gly-Asp (RGD)-containing and hirudin carboxyl terminus-containing synthetic peptide. J. Biol. Chem. 1991, 266, 11975-11979.
16. Owen, T. J.; Broersma, R. J., Jr; Krstenansky, J. L. Trifunctional antithrombin and antiplatelet peptides. WO9429349, 1994.
17. Wienen, W.; Nar, H.; Ries, U. J.; Priepke, H. W. M.; Hauel, N. H.; Stassen, J. M. Pharmacological characterization of BIBR 830ZW: A novel, low molecular weight, synthetic combined inhibitor of thrombin, Factor Xa and platelet aggregation. Presented at the 18th Congress of the International Society of Thrombosis and Haemostasis, July 6-12, 2001, Paris. Thromb. Haemostasis 2001, Suppl.: Abstr. P756.
18. (a) Docking was performed with AutoDock Tools version 3.0.5.
19. (b) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Har, T. W. E.; Belew; R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
20. 1 benzamidine moiety.
21. (b) Evans, H. C.; Perry, C. M.; Faulds; D. Ximelagatran/melagatran - A review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004, 64, 649-678.
22. (c) Eriksson; B. I., Dahl, O. E. Prevention of venous thromboembolism following orthopaedic surgery. Clinical potential of direct thrombin inhibitors. Drugs 2004, 64, 577-595.
23. HyperChem (Release 5.01 for Windows, Hypercube, Inc. 1996).
24. Banner, D. W.; Hadvary, P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. J. Biol. Chem. 1991, 266, 20085-20093.
25. Shridhar, D. R.; Gandhi, S. S.; Rao, S. K. A Facile synthesis of 2-alkyl(aryl)-6- and -7-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazines Synthesis 1982, 986-987.
26. Rutar, A.; Kikelj, D. Selective alkylation of 3-oxo-3,4-dihydro-2H-1,4- benzoxazine-2-carboxylates. Synth. Commun. 1998, 28, 2737-2749.
27. Chiou, S.; Shine, H. J. A simplified procedure for preparing 3,5-di-substituted-1,2,4-oxadiazoles by reaction of amidoximes with acyl chlorides in pyridine solution. J. Heterocycl. Chem. 1989, 26, 125-128.
28. Bolton, R. E.; Coote, S. J.; Finch, H.; Lowdon, A.; Pegg, N.; Vinader, M. V. 3-Substituted-1,2,4-oxadiazolin-5-one; a useful amidine protecting group. Tetrahedron Lett. 1995, 36, 4471-4474.
29. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
30. (b) Lottenberg R.; Hall J. A.; Blinder M.; Binder E. P.; Jackson C. R. The action of thrombin on peptide para-nitroanilide substrates - substrate selectivity and examination of hydrolysis under different reaction conditions. Biochim. Biophys. Acta 1983, 742, 539-557.
31. Addicks, E.; Mazitchek, R.; Giannis, A. Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogues. ChemBioChem 2002, 3, 1078-1088.
32. (a) Kirchhof B.; Kirchhoff U.; Etsheid G. Attempts to standardize platelet aggregation measurements: Simplified screening tests. Haemostasis 1990, 20, 169-180.
33. (b) Thompson S. G., Vickers M. V. Methods in dose response platelet aggregometry. Thromb. Haemostasis 1985, 53, 216-218.